| Catalog No. |
Size |
Price |
Figures |
|---|
Z02018-1 mg
| 1 mg | $ 630.00 |
References:
- Bortolotti F, et al. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome. Gut. Jun 2005; 54(6): 852-857.
- Boni S, et al. Hepatitis C virus core protein acts as a trans-modulating factor on internal translation initiation of the viral RNA. J. Biol. Chem. May 2005; 280(18): 17737-17748.
- Bair RM, et al. Prevalence and risk factors for hepatitis C virus infection among adolescents in detention. Archives of pediatrics & adolescent medicine. Nov 2005; 159(11): 1015-1018.
|
|---|
| Full Name | | Combined Hepatitis C Virus (HCV) |
|
| Abbreviated Name-1 | Combined Hepatitis C Virus (HCV) |
|---|
| Description | E. coli derived recombinant. Combined Hepatitis C Virus (HCV) contains the HCV nucleocapsid, NS3, NS4, and NS5 immunodominant regions. Sequences from 4 gene products (proteins) of the hepatitis C virus (HCV) were scanned by using 3 different PCR-based techniques in search of the most immunoreactive regions suitable for the development of a diagnostic test for the detection of anti-HCV in human sera. The most diagnostically relevant proteins identified in this study were then contructed into one recombinant antigen. |
|---|
| Source | E. coli |
|---|
| Purity | Protein is >95% pure as determined by 10% PAGE (coomassie staining). |
|---|
| Storage | Protein is shipped at ambient temperature. Upon arrival, store at -20°C. |
|---|
| Concentration | 1 mg/ ml in 50 mM Na-PO4, pH 8.5, 2.4 mM EDTA, 5 mM DTT,0.1% SDS. |
|---|
| Stability | Five years frozen. 24 hrs in solution at room temperature. |
|---|
| Specificity | Immunoreactive with sera of HCV- infected individuals. |
|---|
| Applications | Antigen in ELISA and Western blots, excellent antigen for detection of HCV with minimal specificity problems. |
|---|
